NexGel Reports Q2 2026 Results With Adjusted Net Loss
NexGel reported Q2 revenue of $3.69 million and a net loss of $2.87 million. The company is integrating the Celularity transaction, facing supply chain challenges in its BioNX Surgical division, and shifting focus to the hospital market for the SilverSeal product.
View filing at SEC.gov →